Evidence map›Paper›PMID 41894096›Full record

ArticleGeneral thoracic and cardiovascular surgery2026

Impact of Zone 2 preemptive TEVAR on treatment strategy in uncomplicated type B aortic dissection: a 10-year outcome, study of 29 cases with Zone 2 placement.

Ken Nakamura, Kentaro Akabane, Kimihiro Kobayashi, Shusuke Arai, Miku Konaka, Jun Hayashi, Cholsu Kim, Hideaki Uchino, Takao Shimanuki, Tetsuro Uchida

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in General thoracic and cardiovascular surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Ken NakamuraDivision of Cardiovascular Surgery, Nihonkai General Hospital, 30 Akihochou, Sakata City, Yamagata, Japan. ken.nakamura622@gmail.com.ORCID http://orcid.org/0000-0003-1293-7784
Kentaro AkabaneSecond Department of Surgery, Faculty of Medicine, Yamagata University, Yamagata, Japan.
Kimihiro KobayashiSecond Department of Surgery, Faculty of Medicine, Yamagata University, Yamagata, Japan.
Shusuke AraiDivision of Cardiovascular Surgery, Nihonkai General Hospital, 30 Akihochou, Sakata City, Yamagata, Japan.
Miku KonakaSecond Department of Surgery, Faculty of Medicine, Yamagata University, Yamagata, Japan.
Jun HayashiSecond Department of Surgery, Faculty of Medicine, Yamagata University, Yamagata, Japan.
Cholsu KimDivision of Cardiovascular Surgery, Nihonkai General Hospital, 30 Akihochou, Sakata City, Yamagata, Japan.
Hideaki UchinoDivision of Cardiovascular Surgery, Nihonkai General Hospital, 30 Akihochou, Sakata City, Yamagata, Japan.
Takao ShimanukiDivision of Cardiovascular Surgery, Nihonkai General Hospital, 30 Akihochou, Sakata City, Yamagata, Japan.
Tetsuro UchidaSecond Department of Surgery, Faculty of Medicine, Yamagata University, Yamagata, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe indication for preemptive thoracic endovascular aortic repair (TEVAR) is expanding due to improved outcomes in uncomplicated type B aortic dissection (TBAD) compared with best medical therapy (BMT). Long-term outcomes and future treatment strategies for TBAD managed with preemptive TEVAR will be reported. SUBJECTS AND

methodsOf 432 patients with acute TBAD treated at two centers between July 2004 and August 2024, 324 patients who completed acute BMT (1-237 months) were included. Their outcomes were compared with those of patients who did not undergo TEVAR.

resultsOf 324 patients, 277 (control group: CTR) continued BMT and 47 (Zone 2 landing n = 29, Zone 3 landing n = 7, others n = 11) underwent preemptive TEVAR. Propensity score matching was performed to compare the Zone 2 TEVAR group (Z2) with the CTR. There were more patients with patent false lumen in the Z2 (41% vs. 83%, p < 0.05). Pre- and post-TEVAR aortic diameters had decreased from 43.8 ± 6.8 mm to 40.2 ± 10.0 mm (p < 0.001) at 12 months, the same value as the CTR (40.2 ± 11.7 mm). The aortic event free rate (CTR vs. Z2, 1/5/10 years) was 76/69/69% vs. 100/96/96%, respectively, (p < 0.05). Although two patients (7.1%) had aortic events (enlargement of aneurysms) after TEVAR, no aorta-related deaths.

conclusionAmong patients who met the anatomic criteria, long-term outcomes of Zone 2 TEVAR performed during the subacute and early chronic phases were favorable. Preemptive TEVAR may be considered a viable treatment strategy for managing the aortic arch in the early stages of TBAD.

Indexed as

Aortic Aneurysm, ThoracicAortic DissectionBlood Vessel Prosthesis ImplantationDissection, Thoracic AortaEndovascular Aneurysm RepairEndovascular ProceduresAgedFemaleHumansMaleMiddle AgedRetrospective StudiesRisk FactorsTime FactorsTreatment OutcomeAortic aneurysmAortic remodelingBest medical treatmentPreemptive thoracic endovascular aortic repairUncomplicated stanford type B aortic dissection

Identifiers

PMID41894096
PMCPMC13506584

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.